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The success of South Africa (SA)’s prevention of mother-to-child 
transmission of HIV (PMTCT) programme is well documented, 
demonstrating a significant reduction in the early infant transmission 
rate over the past decade from >20% to <2%.[1-4] Much of this 
progress can be attributed to increased access to effective maternal 
antiretroviral therapy (ART) and improved infant prophylactic 
regimens, coupled with robust monitoring and evaluation systems. 
SA’s PMTCT guidelines shifted from recommendations in line with 
World Health Organization (WHO) Option A in 2013, where different 
ART regimens were provided to mothers based on immunological 
profile, to Option B, recommending that all HIV-infected pregnant 
and breastfeeding women be treated with triple ART, and Option B+ 
in 2015, which advocates lifelong triple ART irrespective of CD4+ cell 
count or clinical stage.[5-7] Daily infant nevirapine (NVP) prophylaxis 
for at least 6 weeks’ duration has been part of national guidelines 
since 2010, with infants identified as at high risk recommended either 
extended daily NVP for 12 weeks or dual prophylaxis with NVP plus 
zidovudine (AZT) for 6 weeks.[5-7] Table 1 describes the evolution of 
PMTCT guidelines from 2010 to 2015.[8]
Maternal HIV viral load (VL) has been identified as a strong 
predictor of mother-to-child transmission (MTCT) risk.[9] An infant 
born to a mother who is not virologically suppressed is at increased 
risk of infection and requires high-risk prophylaxis.[7] On account of 
this and the availability of more affordable VL testing,[10] SA reviewed 
its guidelines for treatment monitoring in 2015, recommending that 
all women on ART have a VL test done at confirmation of pregnancy, 
and that women who have been newly initiated on ART have VL 
testing at 3, 6, 12, 18 and 24 months thereafter throughout pregnancy 
and breastfeeding.[7] The early infant diagnosis programme has 
also evolved over the years to enable earlier detection of perinatal 
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Background. Identifying and addressing gaps in the prevention of mother-to-child transmission of HIV (PMTCT) is required if South 
Africa (SA) is to achieve targets for eliminating MTCT (eMTCT). Potential PMTCT gaps that increase MTCT risk include late maternal 
HIV diagnosis, lack of or delayed antiretroviral therapy (ART) during pregnancy and breastfeeding, and lack of effective prophylaxis for 
HIV-exposed infants.
Objectives. To investigate, in near real time, PMTCT gaps among HIV-infected infants in three districts of KwaZulu-Natal Province, SA.
Methods. Between May and September 2016, PMTCT co-ordinators from eThekwini, uMgungundlovu and uMkhanyakude districts 
received daily email notification of all HIV polymerase chain reaction (PCR)-positive results. Co-ordinators reviewed facility records for 
each infant to identify gaps in PMTCT care, including maternal age, timing of maternal HIV diagnosis, maternal treatment history and 
maternal viral load (VL) monitoring. Data were submitted via the mobile phone SMS (text message) service using Rapid Pro technology 
and analysed in Stata 14.
Results. Data on PMTCT gaps were received for 367 (91.8%) of 400 infants with HIV PCR-positive results, within a median time of 
12.5 days (interquartile range (IQR) 6 - 23). The median maternal age was 25 years (IQR 22 - 30), with 48 teenage mothers (15 - 19 years). 
The sample size was too small to determine whether there were significant differences in PMTCT gaps between the 48 teenage mothers and 
293 older (20 - 34 years) mothers. Of the mothers, 220 (60.0%) were first diagnosed prior to conception or at their first antenatal care (ANC) 
visit, and 127 (34.6%) at or after delivery; 137 (37.3%) transmitted HIV to their infants despite receiving >12 weeks of ART. VL results were 
unavailable for 70.0% of women. Only 41 (17.5%) of women known to be HIV-positive during ANC had confirmed virological suppression. 
No statistically significant differences in PMTCT gaps were observed between districts, owing to small sample sizes in uMgungundlovu 
and uMkhanyakude.
Conclusions. The findings highlight the need to improve services during ANC, in particular prioritising maternal VL monitoring. We 
intend to use improved technology to streamline data collection and reporting towards eMTCT.
S Afr Med J 2018;108(4):319-324. DOI:10.7196/SAMJ.2018.v108i4.12630
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infections so as to reduce early childhood morbidity and mortality. 
Current guidelines include routine HIV polymerase chain reaction 
(PCR) testing of all HIV-exposed neonates at birth, followed by 
a repeat HIV PCR at 10 weeks of age and 6 weeks after cessation 
of breastfeeding for those infants who previously tested negative. 
Infants who test positive should be fast-tracked within the treatment 
programme so that ART can be initiated within 7 days of diagnosis, 
with confirmatory HIV PCR testing performed on the same day.[7]
Despite having a robust evidence-based PMTCT policy framework, 
SA’s progress towards eliminating mother-to-child transmission 
of HIV (eMTCT) is considerably challenged because of very high 
maternal HIV prevalence,[11] including high rates of seroconversion 
during pregnancy and breastfeeding.[12,13] Even with a low early 
MTCT transmission rate of ~1.5% among HIV-infected mothers,[4] 
recent laboratory data suggest that the national intrauterine infection 
rate is already five times higher than the WHO eMTCT target of 
<50 HIV-infected infants per 100 000 live births.[14,15] As intrapartum 
and postnatal transmission probably account for at least half of all 
MTCT,[16,17] it is clear that SA has a considerable way to go before 
achieving eMTCT. Towards realising this end, the country must not 
only tackle the high HIV incidence among pregnant and breastfeeding 
women, particularly adolescent and young mothers (15 - 24 years),[18] 
but also identify potential gaps in the PMTCT cascade and develop 
targeted interventions to reduce new paediatric HIV infections. Gaps 
identified in the PMTCT cascade that facilitate MTCT include late 
HIV diagnosis in pregnant women and subsequent lack of or delay 
in ART initiation during pregnancy.[13,19,20] These factors preclude the 
sufficient time on ART required to suppress maternal viraemia to 
levels protective against MTCT risk during pregnancy, at delivery, 
and during the postpartum period while breastfeeding. Additional 
potential PMTCT gaps include lack of virological suppression 
among women already on ART, inadequate prophylaxis for exposed 
infants, and discontinuation of care by mother-infant pairs (MIPs) 
postpartum.[20] Among social factors, youth pregnancy has been 
associated with an increased risk of MTCT.[18]
Mobile health (mHealth) technologies provide an opportunity for 
rapid identification of PMTCT gaps for intervention and subsequent 
improvement in service delivery.[21] For infants who are already 
infected, improved case-finding can lead to accelerated entry into 
and retention in care.[22,23] It is in response to the latter that automated 
HIV PCR Results for Action (RfA) reports from the National Health 
Laboratory Service (NHLS) Corporate Data Warehouse (CDW) 
have been routinely generated since June 2015. The HIV PCR RfA 
reports contain all laboratory-authorised HIV PCR results (including 
specimen reference numbers) for a particular region (e.g. health 
facility or district) and include patient demographic details (including 
name, surname, date of birth and age) and geographical location 
(health facility and patient contact details, including address and 
telephone number). These password-protected reports are routinely 
emailed on a weekly basis to PMTCT co-ordinators in the provincial 
and district health departments for active tracing and linkage to care 
of all HIV PCR-positive infants.
Objectives
To report findings from an operational study that aimed to describe, 
in near real time, potential reasons for MTCT among HIV-infected 
infants aged <18 months in three districts of KwaZulu-Natal (KZN) 
Province, SA.
Methods
Study population
The study was conducted among HIV-infected MIPs identified 
in three districts in KZN, namely eThekwini, uMgungundlovu 
and uMkhanyakude. In 2013, these three districts were among six 
districts with the highest antenatal burden of HIV in SA, each having 
a prevalence of >40%.[11] eThekwini and uMgungundlovu are large 
Table 1. Evolution of the South African PMTCT guidelines for HIV-infected pregnant women and HIV-exposed infants aged  
<18 months, 2010 - 2015
2010, WHO Option A 2013, WHO Option B 2015, WHO Option B+
Maternal ART 1. If CD4+ <350 cells/µL or WHO 
stage III or IV: initiate ART lifelong
2. If CD4 >350 cells/µL:
• AZT at 14 weeks’ gestation
• Single-dose NVP + AZT/3TC at 
onset of labour
• AZT/3TC daily for 7 days 
postpartum
All pregnant and breastfeeding 
HIV-infected women initiated on 
ART for duration of pregnancy and 
breastfeeding
1. If CD4+ >350 cells/µL: continue 
ART until 1 week post cessation of 
breastfeeding
2. If CD4 <350 cells/µL: continue ART 
lifelong
All pregnant and breastfeeding HIV-
infected women initiated on lifelong 
ART
Infant prophylaxis Single-dose NVP daily for 6 weeks 
if mother is on ART or for duration 
of breastfeeding + 1 month post 
cessation of breastfeeding
Single-dose NVP daily for 6 weeks 1. Low risk: Daily dose NVP for  
6 weeks 
2. High risk:
• NVP for 12 weeks if mother is 
on cART <4 weeks, or newly 
diagnosed at delivery
• NVP + AZT for 6 weeks if 
maternal VL >1 000 cps/mL
• NVP + AZT if newly diagnosed 
while breastfeeding. If HIV PCR is 
negative, continue NVP for a total 
of 12 weeks
PMTCT = prevention of mother-to-child transmission; WHO = World Health Organization; ART = antiretroviral therapy; AZT = zidovudine; NVP = nevirapine; 3TC = lamivudine; VL = viral 
load; PCR = polymerase chain reaction; cps/mL = copies per mL of blood.
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metropolitan districts, while uMkhanyakude 
is rural and one of the poorest districts in 
the country.[24]
Study design and data collection
This was an operational study in which 
a retrospective review of medical records 
of MIPs was conducted over a 5-month 
period from 1 May to 30 September 2016. 
For the purposes of this study, HIV PCR 
RfA reports from the NHLS CDW were 
emailed daily to the PMTCT co-ordinators 
and used to identify all HIV PCR-positive 
infants for linkage to care and inclusion in 
the study. MIP PMTCT data recorded in 
facility-based patient medical records and 
the national HIV electronic register (Tier.
net) were retrospectively reviewed to answer 
five questions considered to be potential 
gaps for MTCT (Fig. 1).
The five questions focused on current 
maternal age, timing of maternal diagnosis 
in relation to the pregnancy, maternal ART 
treatment history, most recent maternal 
VL and the infant prophylaxis prescribed. 
Rapid Pro, an open-source communication 
platform that allows for collection of data 
via the mobile phone SMS (text message) 
service was used. The HIV PCR specimen 
reference number from the HIV PCR RfA 
report was used to identify linked MIP 
data. Once the PMTCT co-ordinators had 
been notified of an HIV PCR-positive infant 
in their district, they contacted the facility 
at which the infant’s blood specimen had 
been collected and requested facility staff 
to provide answers to the questionnaire, or 
travelled to the facility and reviewed the 
records themselves. The district PMTCT 
co-ordinators then SMSed the HIV PCR 
specimen reference number to a short code 
number that triggered Rapid Pro to initiate 
the mobile phone-based questionnaire. Data 
for each HIV PCR-positive MIP were stored 
in Rapid Pro for near-real-time analysis. We 
aimed for a turnaround time of 3 working 
days from the time of notification of positive 
HIV PCRs by RfA reports to completing the 
questionnaire in Rapid Pro. Only the first 
HIV PCR-positive test per infant during 
the study period was included. Repeat 
confirmatory HIV PCR tests, indeterminate 
specimens (those that were neither positive 
nor negative) and tests registered outside the 
study period were excluded from enrolment.
Statistical analysis
Rapid Pro data were exported into Excel 
2010 (Microsoft, USA), merged with HIV 
PCR RfA report data, and imported into 
Stata 14 (StataCorp, USA) for analysis. 
Descriptive statistics were conducted to 
describe the cohort. Continuous variables 
were described using medians and inter-
quartile ranges (IQRs), while categorical 
data were described using proportions and 
compared using Pearson’s χ2 test, or Fisher’s 
exact test for sparse data.
Ethics clearance
The study was approved by the Human 
Research Ethics Committee of the University 
of the Witwatersrand (ref. no. M160216) 
and the Health Research Committee 
of the KZN Department of Health (ref. 
no. HRKM100/16). Patient consent was not 
required, as the study was an audit of routine 
clinical care within a national healthcare 
programme. All information was de-identi-
fied prior to data analysis.
Results
Mother-infant pairs
Out of a total of 400 infants with positive 
HIV PCR test results, 367 (91.8%) were inclu-
ded in the study as determined by available 
MIP PMTCT data (Fig. 2): 258 (70.3%) 
from 69 facilities in eThekwini, 58 (15.8%) 
from 21 facilities in uMgungundlovu and 51 
(13.9%) from 34 facilities in uMkhanyakude. 
Infant age at testing varied, with 178 (48.5%) 
results performed at <3 months of age, 105 
(28.6%) infants having been tested within 
the first 6 days of life. Data were received 
within a median of 12.5 days (IQR 6 - 23) 
from the time district PMTCT co-ordinators 
What is the maternal 
age in years?
• Enter a number between 
  8 and 60 inclusive
When was the mother rst 
diagnosed with HIV?
• Prior to this pregnancy
• During this pregnancy at 
  ANC HIV rst test
• During this pregnancy at 
  ANC HIV re-test
• During breastfeeding 
  after delivery
For how many weeks did 
the mother receive cART 
during pregnancy?
• No ART
• During delivery
• <4 weeks
• 4 - 12 weeks
• >12 weeks
What was the last 
maternal VL result?
• Undetectable
• <1 000 cps/mL
• 1 000 - 10 000 cps/mL
• >10 000 cps/mL
• Not done
What prophylaxis was 
prescribed for the baby?
• 6 weeks’ NVP
• 12 weeks’ NVP
• 6 weeks’ NVP and AZT
• None
Fig. 1. The mobile phone-based questionnaire used to collect study data. (ANC = antenatal care; (c)ART = (combination) antiretroviral therapy; VL = viral 
load; cps/mL = copies per mL blood; NVP = nevirapine; AZT = zidovudine.)
 Total
(132 facilities)
550
150
400
33
367 (100%)
(124 facilities)
eThekwini
(72 facilities)
388
109
279
21
258 (70.3%)
(69 facilities)
uMgungundlovu
(23 facilities)
87
21
66
8
58 (15.8%)
(21 facilities)
uMkhanyakude
(37 facilities)
75
20
55
4
51 (13.9%)
(34 facilities)
HIV PCR-positive tests identied 
from the NHLS CDW
Number of conrmatory HIV PCR 
test results excluded
Number of unique HIV PCR results 
linked to MIPs
Number of infants without PMTCT 
data excluded
Eligible positive MIPs
Fig. 2. Description of how the study cohort was obtained from the original dataset. (PCR = polymerase 
chain reaction; NHLS CDW = National Health Laboratory Service Corporate Data Warehouse; 
PMTCT = prevention of mother-to-child transmission of HIV; MIPs = mother-infant pairs.)
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were notified of a positive HIV PCR result, with 89.9% collected via 
SMS using Rapid Pro and the remainder via email.
Prevention of mother-to-child transmission gaps
Table 2 describes maternal and infant characteristics of the study 
cohort. The median age for mothers whose infants tested HIV PCR-
positive was 25 years (IQR 22 - 30), with only 48 (13.1%) being 
teenage mothers (15 - 19 years). The sample size was too small to 
determine whether there were significant differences in PMTCT 
gaps between the 48 teenage mothers and 293 older mothers (20 - 34 
years).
Of the 367 women, 220 (60.0%) were first diagnosed prior to 
conception or at their first antenatal care (ANC) visit, 14 (3.8%) at a 
later ANC visit, and 127 (34.6%) at or after delivery; in 6 cases (1.6%) 
no information was available. Overall, 218 women (59.4%) received 
ART prior to delivery, with 137 (37.3%) receiving >12 weeks of 
therapy. Of 134 women (36.5%) who did not receive ART, 17 (12.7%) 
were diagnosed prior to conception or at their first ANC visit, 22 
(16.4%) at delivery and 95 (70.9%) during breastfeeding.
A total of 110 women in the study (30.0%) had a documented VL. 
Of these, 45 (40.9%) were virologically suppressed as defined by a VL 
<1 000 copies per mL. Of the 234 women known to be HIV-positive 
during ANC, 98 (41.9%) had a documented VL and 41 (41.8%) were 
virologically suppressed, the latter group accounting for 11.2% of all 
transmissions. Of 137 women who received >12 weeks of ART, 75 
(54.7%) had documented evidence of VL monitoring.
Of the 284 (77.4%) infants with documented evidence that 
prophylaxis had been prescribed, 177 (62.3%) and 107 (37.7%) 
received low- and high-risk prophylaxis (as defined in Table 1), 
respectively. The majority of infants for whom no prophylaxis was 
prescribed were born to women diagnosed during breastfeeding. 
Among 30 infants (8.2%) born to women diagnosed during 
delivery, and therefore known to be at increased risk for MTCT, 20 
(66.7%) received high-risk prophylaxis, 8 (26.7%) received low-risk 
prophylaxis and 2 (6.7%) received none.
We did not observe any statistically significant differences in 
responses to the PMTCT gap questions between the three districts, 
owing to small sample sizes in uMgungundlovu and uMkhanyakude; 
facility-level data were too sparse to demonstrate any differences 
either. The median number of PCR-positive tests per facility was 2 
(IQR 1 - 3) for eThekwini, 1 (IQR 1 - 3) for uMgungundlovu and 
1 (IQR 1 - 2) for uMkhanyakude. An analysis involving outlier 
facilities (facilities with PCR-positive tests greater than their district’s 
75th percentile number) showed no statistical differences in either 
Table 2. Description of maternal and infant characteristics of the study cohort
Maternal age (years)
Characteristic Total (N=367) 15 - 19 (n=48) 20 - 34 (n=293) p-value
Age of infant at first HIV PCR-positive test (months) 0.11
Median (IQR) 3.3 (0.1 - 9.9) 4.3 (0.8 - 10.5) 2.9 (0.1 - 9.6)
<3, n (%) 178 (48.5) 18 (37.5) 148 (50.5)
3 - <6, n (%) 55 (15.0) 9 (18.8) 43 (14.7)
6 - <12, n (%) 68 (18.5) 11 (22.9) 48 (16.4)
12 - <18, n (%) 66 (18.0) 10 (20.8) 54 (18.4)
Timing of maternal HIV diagnosis, n (%) 0.05
Prior to current pregnancy 87 (23.7) 3 (6.3) 69 (23.6)
During current pregnancy at ANC HIV first test 133 (36.2) 23 (47.9) 106 (36.2)
During current pregnancy at ANC HIV re-test 14 (3.8) 1 (2.1) 13 (4.4)
During current pregnancy at delivery 30 (8.2) 3 (6.3) 26 (8.9)
During breastfeeding 97 (26.4) 18 (37.5) 74 (25.3)
Unknown 6 (1.6) 0 5 (1.7)
Maternal treatment history, n (%) 0.29
No ART 134 (36.5) 22 (45.8) 103 (35.2)
ART during delivery 7 (1.9) 0 6 (2.1)
ART <4 weeks 24 (6.5) 5 (10.4) 18 (6.1)
ART 4 - 12 weeks 57 (15.5) 8 (16.7) 45 (15.4)
ART >12 weeks 137 (37.3) 13 (27.1) 114 (38.9)
Unknown 8 (2.2) 0 7 (2.4)
Last recorded maternal VL result (cps/mL), n (%) 0.24
Undetectable 21 (5.7) 0 19 (6.5)
<1 000 24 (6.5) 2 (4.2) 21 (7.2)
1 000 - 10 000 21 (5.7) 3 (6.3) 16 (5.5)
>10 000 44 (12.0) 6 (12.5) 33 (11.3)
Did not have a documented VL 257 (70.0) 37 (77.1) 204 (69.6)
Infant prophylaxis, n (%) 0.53
6 weeks’ NVP 177 (48.2) 21 (43.8) 143 (48.8)
12 weeks’ NVP 31 (8.5) 3 (6.3) 24 (8.2)
6 weeks’ NVP + AZT 76 (20.7) 11 (22.9) 60 (20.5)
None 72 (19.6) 13 (27.1) 57 (19.5)
Unknown 11 (3.0) 0 9 (3.1)
PCR = polymerase chain reaction; IQR = interquartile range; ANC = antenatal care; ART = antiretroviral therapy; VL = viral load; cps/mL = copies per mL of blood; NVP = nevirapine; 
AZT = zidovudine.
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the proportions of outlier facilities (p=0.57) or the median number 
of PCR-positive tests recorded (16 (6.2%) for outlier facilities 
in eThekwini, 3 (5.2%) in uMgungundlovu and 5 (9.8%) in 
uMkhanyakude) (p=0.07).
Prevention of mother-to-child transmission cascade
Fig. 3 illustrates the cascade of PMTCT services, demonstrating that 
36.3% of HIV-positive infants were born to mothers diagnosed late, 
either at delivery or during breastfeeding, with an additional 26.6% of 
mothers receiving <12 weeks of ART prior to delivery. A further 1.5% 
of these infants were not prescribed any antiretroviral prophylaxis. In 
total, 131 HIV transmissions (35.6%) occurred despite both maternal 
and infant PMTCT care having been received.
Discussion
The findings of this study reveal critical gaps in the PMTCT cascade 
that require urgent intervention as SA works towards eMTCT. 
Whereas it is well documented that timing of maternal HIV 
diagnosis and subsequent access to ART are strong predictors of HIV 
transmission,[19,20,25-27] our findings suggest that the majority of MTCT 
occurred among women who accessed HIV testing services at their 
first ANC visit, with a quarter already having been diagnosed prior to 
conception. At the opposite end of the spectrum, a third of infections 
occurred among women diagnosed at delivery or during breastfeeding. 
However, it could not be ascertained what proportion of these were due 
to incident HIV infections or failure to access timeous ANC, owing to 
data being unavailable in this study. Regarding treatment monitoring, 
only 30.0% of mothers had at least one VL result. Even among 
mothers who received >12 weeks of ART, only 54.7% had evidence 
of VL monitoring, with less than half of those with VL test results 
available being virologically suppressed. In total, 12.3% of transmitting 
mothers had documented evidence of VL suppression. As maternal 
VL is associated with risk of MTCT,[9] and is used to inform the infant 
PMTCT regimen,[7] poor maternal treatment monitoring during the 
antenatal period jeopardises the success of the PMTCT programme.
These findings are indicative of severe shortcomings in health 
services relating to the prevention and planning of pregnancies, 
management of HIV in women of reproductive age, and provision of 
optimal PMTCT care to MIPs. As VL monitoring during pregnancy 
has only recently been included in national guidelines, the lack of 
documented virological testing may represent slow uptake of current 
recommendations, which were previously focused on monitoring 
CD4+ counts. It may also reflect health system challenges, including 
poor record-keeping and result retrieval practices. However, the 
fact that infants born to newly diagnosed mothers were prescribed 
standard prophylaxis suggests that guidelines are not being adhered 
to, possibly owing to complexity of recommendations and poor 
understanding of risk stratification. It is anticipated that the 
availability of point-of-care VL testing during ANC and postnatal 
care may assist in the future by facilitating ready access to maternal 
VL testing and rapid turnaround time of results.
Although we aimed to receive PMTCT gap data within 3 working 
days, data were received only after a median of 12.5 days. Delays 
were attributed to technological failures (e.g. poor network coverage 
and delayed transfer of data into Rapid Pro) and poor record-
keeping at facility level. These results demonstrate that true real-
time programme monitoring will require mHealth tools that are 
not dependent on continuous network availability and manual data 
entry. In addition, programme data will need to be centralised, with 
automated merging, analysis and reporting that feeds back to users 
timeously. Although near-real-time monitoring was not achieved, 
thereby potentially delaying efforts to identify MTCT high-burden 
areas and implement rapid targeted interventions, no differences in 
PMTCT gaps were observed between the three districts, or at facility 
level within each district. These results suggest that widespread 
enhancement of PMTCT services will be required if eMTCT is to 
be achieved. However, district sample volumes did not allow for 
sufficient power to determine whether differences were statistically 
significant. In addition, this study only included three districts in 
SA, so findings may not be representative of the country as a whole.
Study limitations
We acknowledge a number of limitations in this study. Whereas 
~50% of infants were first diagnosed at <3 months of age, with 28.6% 
diagnosed at or soon after birth, our results may not represent the 
true age distribution of HIV-infected infants, as we only included 
the first HIV PCR-positive test performed during the study period. 
We were therefore unable to ascertain whether infections were 
intrauterine, intrapartum or postpartum. Study findings were 
restricted to HIV-infected infants only, thereby precluding an HIV-
exposed uninfected control group for comparison. While younger 
maternal age has previously been associated with an increased risk 
of MTCT,[18,20,28] we did not find significant differences in responses 
between teenage and older mothers on account of the small size of the 
study population and the lack of a control group. Furthermore, the 
number and depth of the questions asked in the study were limited by 
the data collection software used, resulting in too few data to explain 
why 36.2% of infants became infected despite being born to mothers 
who received >12 weeks of ART. For instance, we did not have data 
on maternal ART adherence, gestational age at first ANC visit, when 
maternal VL testing was performed in relation to delivery, or drug 
resistance profiles. We also did not have data on infant feeding or 
frequency of HIV testing during pregnancy to determine whether 
infections diagnosed late in pregnancy or during breastfeeding were 
incident infections or due to failure to access timeous ANC. Lastly, 
as this was a retrospective study, it was not possible to distinguish 
between what was documented and what actually occurred. Among 
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Fig. 3. Cascade of PMTCT services in the study cohort. This figure tracks 
the flow of HIV-positive MIPs along the continuum of PMTCT care in the 
three districts. (A = total MIPs with positive infant HIV PCR; B = total 
MIPs where maternal HIV infection was diagnosed prior to pregnancy or 
during ANC (first HIV test and re-test); C = total MIPs where maternal 
ART received for >12 weeks; D = total infant prophylaxis where maternal 
ART received for >12 weeks; PMTCT = prevention of mother-to-child 
transmission of HIV; MIPs = mother-infant pairs; PCR = polymerase chain 
reaction; ANC = antenatal care; ART = antiretroviral therapy.)
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women without evidence of VL monitoring, we therefore could not 
determine whether VLs were not done or simply not recorded at 
facility level or captured on Tier.net.
Conclusions
Two-thirds of the mothers who transmitted HIV to their infants did 
so despite receiving PMTCT services. The PMCT gaps outlined in 
this article highlight the need to improve quality of services during 
ANC as well as to prevent maternal infections postpartum. The focus 
of maternal PMTCT care needs to shift towards the prevention and 
planning of pregnancies as well as better management of HIV in women 
of reproductive age, including VL monitoring and intensified treatment 
adherence support. We intend using improved mHealth technologies to 
streamline data collection and reporting towards eMTCT.
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